Myeloma Stratification and Risk-Adapted Therapy with Reflex to Measurable/Minimal Residual Disease, Bone Marrow
Use
This test is useful for the risk stratification of patients with treated multiple myeloma, aiding in determining treatment and management decisions with reflex to measurable residual disease assessment for more sensitive analysis. It also supports risk stratification of patients with newly diagnosed multiple myeloma.
Special Instructions
Not provided.
Limitations
This test is designed for patients with multiple myeloma and may not be applicable for monoclonal gammopathy of uncertain significance, smoldering myeloma, or amyloidosis. It should not replace existing prognostic systems like the International Staging System. The percentage of clonal plasma cells estimated by flow cytometry can be affected by specimen processing and antigen loss over time.
New York Approved
Methodology
Cell-based / Cytometry (Flow Cytometry)
Biomarkers
LOINC Codes
- 93363-0 - PC DNA content + prolif Pnl Mar FC
- 93362-2 - Monotypic plasma cells Mar FC
- 93021-4 - PC.abnormal/Cells NFr Mar FC
- 93361-4 - Mono PC in S Phs NFr Mar FC
- 93360-6 - Monotypic PC DNA index Mar FC-Rto
- 93359-8 - Monotypic PC DNA ploidy Mar FC
- 93358-0 - Polyclonal PCs/Cells NFr Mar FC
- 93020-6 - Polyclonal PCs/Total PCs NFr Mar FC
- 22637-3 - Path report.final Dx Spec
Result Turnaround Time
1-13 days
Related Documents
For more information, please review the documents below
Specimen
Bone Marrow
Volume
4 mL
Minimum Volume
3 mL
Container
Yellow top (ACD solution A or B) preferred, Lavender top (EDTA) acceptable
Causes for Rejection
Gross hemolysis, Fully clotted
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 72 hours |